IP Library Granted Patent US 11,242,553
Granted Patent B2
US 11,242,553 · App. 14/761,791 · Granted Feb 8, 2022

MiRNA targets

Inventors: Judy Lieberman (Brookline, MA); Shen Mynn Tan (Newton, MA)
Assignee: Children's Medical Center Corporation
C12Q1/6816C12N15/1006C12N15/113C12Q1/6886C12N2310/141C12Q2600/178
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,242,553
App. No.
14/761,791
Granted
Feb 8, 2022
Kind
B2
Abstract

The present invention provides systems and methods for identifying, isolating, and/or characterizing microRNAs, their targets, and microRNA response elements, and for predicting their biological function.

Claims (17)

1. A method of identifying miRNA response elements (MREs), the method comprising:

conducting an affinity assay and a sequencing assay comprising the following steps:

(a) transfecting a cell with a biotinylated miRNA, wherein the biotinylated miRNA binds to an RNA target sequence and forms a biotinylated miRNA-RNA complex inside the cell;

(b) lysing the cell in lysis buffer containing a macromolecular crowding agent;

(c) isolating the biotinylated miRNA-RNA complex by binding the biotinylated miRNA in the complex to streptavidin-coated beads in the presence of the macromolecular crowding agent;

(d) generating a biotinylated miRNA-RNA fragment by contacting the biotinylated miRNA-RNA complex attached to streptavidin-coated beads with an RNase under conditions sufficient to degrade single stranded RNA associated with the miRNA-RNA complex into RNA fragments and a bead-bound biotinylated miRNA-RNA fragment complex;

(e) separating the bead-bound biotinylated miRNA-RNA fragment complex from single stranded RNA fragments;

(f) extracting the RNA fragment from the bead; and

(g) sequencing each nucleic acid sequence of the extracted RNA fragments wherein each extracted RNA fragment represents an miRNA response element; thereby

(h) identifying the miRNA response element nucleic acid sequence.

2. The method of claim 1 , wherein the macromolecular crowding agent is one or more of Ficoll PM400, Ficoll PM70, dextran sulfate, Ficoll (Fc) 70 kDa (Fc70), Fc400 kDa (Fc400), trehalose, proline, polyethylene glycol (PEG) 4 kDa, and Dextran 670 kDa.

3. The method of claim 1 , wherein the isolating step is performed in the presence of EDTA.

4. The method of claim 1 , wherein the RNase is one or more of RNase T1, RNase A, RNase If, MNase, or an RNase capable of degrading single-stranded RNA.

5. The method of claim 1 , wherein the miRNA-RNA complex is contacted with the RNase for 5, 10, 15, 20, 25, 30, 45, or 60 minutes.

6. The method of claim 1 , wherein the RNA fragment sequence ranges in length of 5-500, 5-250, 10-100, or 15-60 nucleotides.

7. The method of claim 1 , wherein the nucleic acid sequence of the extracted RNA fragment is determined by ion semiconductor sequencing, pyrosequencing, sequencing by synthesis, sequencing by ligation, or chain termination sequencing.

8. The method of claim 1 , wherein the miRNA is selected from the group consisting of: miR-522, miR24, miR34a and let-7a.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 13, 2020
From: LIEBERMAN, JUDY; TAN, SHEN MYNN
To: CHILDREN'S MEDICAL CENTER CORPORATION
Reel/Frame 054358/0745 →
Continuity (2)
Provisional Application 61754392 · Jan 18, 2013
Related Publication 20150353991A1 · Dec 10, 2015